R&D Integrate or isolate: Incorporating traditional safety-relat... Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?
News Adcomm backs Replimune melanoma drug, despite data concern Replimune's RP1 immunotherapy for melanoma clears advisory committee vote by 10 to three, despite FDA concerns about the design of the IGNYTE study.
News Lawmakers seek answers from RFK on Gardasil shot settlement Four Democratic senators are investigating whether the family of HHS Secretary RFK Jr is profiting from what they assert are "bogus" vaccine lawsuits.
News FDA advisors vote no to Capricor's DMD therapy FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
News Re-rostered FDA committee backs peptide compounding Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.